Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AAO | American Academy of Ophthalmology |
| ACI | Annual cumulative incidence |
| ACM | Annual cumulative mortality |
| ADI | Area Deprivation Index |
| AE | Adverse event |
| AGIS | Advanced Glaucoma Intervention Study |
| AHFS | American Hospital Formulary Service |
| ALT | Argon laser trabeculoplasty |
| AMA | American Medical Association |
| AMD | Age-related macular degeneration |
| API | Active pharmaceutical ingredient |
| ASC | Ambulatory surgery center |
| ASCRS | American Society of Cataract and Refractive Surgery |
| ASP | Average sales price |
| BAC | Benzalkonium chloride |
| BAK | Benzalkonium chloride |
| BCDVA | Best-corrected distance visual acuity |
| BCVA | Best-corrected visual acuity |
| BID | Twice daily |
| BIM-DRS | Bimatoprost Drug Ring System |
| BIM-IOL | Bimatoprost Drug Pad-Intraocular Lens |
| CCT | Central corneal thickness |
| CDC | Centers for Disease Control and Prevention |
| CDER | Center for Drug Evaluation and Research |
| CDRH | Center for Devices and Radiological Health |
| CECD | Corneal endothelial cell density |
| CEIOL | Cataract extraction with intraocular lens implantation |
| CFB | Change from baseline |
| CHF | Congestive heart failure |
| CI | Confidence interval |
| CIGTS | Collaborative Initial Glaucoma Treatment Study |
| CMO | Contract manufacturing organization |
| CMS | Centers for Medicare & Medicaid Services |
| COAG | Chronic open-angle glaucoma |
| CPT | Current Procedural Terminology |
| CrI | Credible interval |
| CS | Cataract surgery |
| CU | Regents of the University of Colorado |
| D | Diopter |
| DIOP | Diurnal intraocular pressure |
| ECP | Endoscopic cyclophotocoagulation |
| ED | Emergency department |
| EGS | European Glaucoma Society |
| EMGT | Early Manifest Glaucoma Trial |
| EUR | Euro |
| FDA | US Food and Drug Administration |
| FDCA | Federal Food, Drug, and Cosmetic Act |
| FE | Fast-eluting |
| FFS | Fee-for-service |
| FIH | First-in-human |
| GAPS | Glaucoma Adherence and Persistency Study |
| GBD | Global Burden of Disease |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| HCPCS | Healthcare Common Procedure Coding System |
| HEDIS | Healthcare Effectiveness Data and Information Set |
| HFHS | Henry Ford Health System |
| HMS | Hydrus Microstent |
| HOPD | Hospital outpatient department |
| HR | Hazard ratio |
| IGC | Interventional Glaucoma Consortium |
| IND | Investigational New Drug application |
| IOL | Intraocular lens |
| IOP | Intraocular pressure |
| IPO | Initial public offering |
| IQR | Interquartile range |
| LALES | Los Angeles Latino Eye Study |
| LiGHT | Laser in Glaucoma and Ocular Hypertension Trial |
| MD | Mean deviation |
| MIGS | Minimally invasive glaucoma surgery |
| MIPS | Merit-based Incentive Payment System |
| MPR | Medication possession ratio |
| MSVI | Moderate or severe vision impairment |
| MVC | Motor vehicle collision |
| NA | Not applicable |
| NCE | New chemical entity |
| NDA | New Drug Application |
| NEI | National Eye Institute |
| NEI VFQ-25 | National Eye Institute 25-item Visual Function Questionnaire |
| NHANES | National Health and Nutrition Examination Survey |
| NICE | National Institute for Health and Care Excellence |
| NOAEL | No observed adverse effect level |
| OAG | Open-angle glaucoma |
| OHT | Ocular hypertension |
| OHTS | Ocular Hypertension Treatment Study |
| ONH | Optic nerve head |
| OOI | Other ocular imaging |
| OR | Odds ratio |
| OSD | Ocular surface disease |
| OSDI | Ocular Surface Disease Index |
| PACG | Primary angle-closure glaucoma |
| PDC | Proportion of days covered |
| PG | Pigmentary glaucoma |
| PGA | Prostaglandin analog |
| PHQ-9 | Patient Health Questionnaire-9 |
| POAG | Primary open-angle glaucoma |
| PTVT | Primary Tube Versus Trabeculectomy Study |
| PXG | Pseudoexfoliation glaucoma |
| Q4H, Q6H, Q8H | Every 4, 6, or 8 hours |
| QALY | Quality-adjusted life-year |
| QoL | Quality of life |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| RNFL | Retinal nerve fiber layer |
| RR | Relative risk or rate ratio |
| SD | Standard deviation |
| SE | Slow-eluting |
| SEC | US Securities and Exchange Commission |
| SEE | Support, Educate, Empower |
| SES | Socioeconomic status |
| SF-12 | 12-item Short-Form Health Survey |
| SLR | Systematic literature review |
| SLT | Selective laser trabeculoplasty |
| TAGS | Treatment of Advanced Glaucoma Study |
| TEAE | Treatment-emergent adverse event |
| Tx | Treatment arms |
| UI | Uncertainty interval |
| UKGTS | United Kingdom Glaucoma Treatment Study |
| UM | University of Michigan |
| USD | United States dollar |
| USP | United States Pharmacopeia |
| UV | Ultraviolet |
| VF | Visual field |
| VFI | Visual field index |
| VFQ | Visual Function Questionnaire |
| VI | Visual impairment |
| VL | Vision loss |
| VRQoL | Vision-related quality of life |
| ZBI-22 | 22-item Zarit Burden Interview |